Patents

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2012/0093863 HCV VACCINES AND METHODS FOR USING THE SAME
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a,...
2012/0093862 NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION
The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include...
2012/0093861 NOROVIRUS VACCINE FORMULATIONS
The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and...
2012/0093860 INFLUENZA VACCINES WITH INCREASED AMOUNTS OF H3 ANTIGEN
An influenza vaccine includes an increased amount of H3N2 antigen relative to the normal dose. In a typical embodiment, the vaccine includes hemagglutinins from...
2012/0093859 INFLUENZA VACCINE REGIMENS FOR PANDEMIC-ASSOCIATED STRAINS
In contrast to known regimens where pandemic-associated antigens are given 3-4 weeks apart for immunisation, according to the invention two doses of a...
2012/0093858 Tat-Based Tolerogen Compositions and Methods for Making and Using Same
A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of...
2012/0093857 Vaccination and Immunotherapy as New Therapeutic Modalities in the Treatment of Glaucoma
This invention provides a method whereby a vaccine, particularly a vaccine based on a prophylactic or therapeutic AIDS/HIV vaccine, or other immune-reactive...
2012/0093856 METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE...
A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or...
2012/0093855 RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF
The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples,...
2012/0093854 USE OF MYCOPLASMA BOVIS ANTIGEN
The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against...
2012/0093853 Simian Adenovirus Vectors and Methods of Use
A recombinant vector comprises a simian adenovirus capsid and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian...
2012/0093852 NON-LIPIDATED VARIANTS OF NEISSERIA MENINGITIDIS ORF2086 ANTIGENS
The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary...
2012/0093851 CHLAMYDIA ANTIGENS
The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides...
2012/0093850 COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
Staphylococcus aureus Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also...
2012/0093849 Agents for Treatment of HCV and Methods of Use
An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic...
2012/0093848 IMMUNOGENIC COMPOSITION COMPRISING PEPTIDES DERIVED FROM CYTOMEGALOVIRUS AND THE USE THEREOF
The present invention provides (poly)peptides, which are recognized by human cytomegalovirus (CMV)-specific immune cells. The present invention further provides...
2012/0093847 RECOMBINANT RSV VACCINES
This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g.,...
2012/0093846 PROTEIN FOR THE IMMUNOCASTRATION FOR MAMMALS
Fusion protein for immunocastration (Sequences 1a and 1b) that comprises the primary amino acid sequence of the gonadotrophin-liberating protein fused to a...
2012/0093845 NEIL3 PEPTIDES AND VACCINES INCLUDING THE SAME
The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes...
2012/0093844 ANTIMICROBIAL PEPTIDES BASED ON CMAP27
The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27...
2012/0093843 TEM8 PEPTIDES AND VACCINES COMPRISING THE SAME
According to the present invention, peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 9, 23, 25, 30, 60, 63 or 68 were demonstrated to have...
2012/0093842 CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH
Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a...
2012/0093841 Her2 DNA Vaccine as Adjunct Treatment for Cancers in Companion Animals
The application discloses therapeutic vaccines based upon the "pING" DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to...
2012/0093840 TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS
The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with...
2012/0093839 NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF
In a broad aspect the present invention generally relates to novel dimer-complexes (herein called "non-fused-dimers" or NFDs) comprising single variable...
2012/0093838 GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO A HER2 ANTIBODY CANCER THERAPY
The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene...
2012/0093837 COMPOSITIONS AND METHODS FOR DETECTING EGFR IN CANCER
The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and...
2012/0093836 PHARMACEUTICAL COMPOSITIONS FOR TREATING METASTASIS
The present invention relates to the use of an antifungal agent or of a compound capable of binding to a mannoprotein and blocking the binding of said...
2012/0093835 ANTI-INFLAMMATORY ANTIBODIES AND USES THEREFOR
The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders.
2012/0093834 NEUTRALIZING MOLECULES TO VIRAL ANTIGENS
The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the...
2012/0093833 Human Oncostatin M Antibodies and Methods of Use
Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin...
2012/0093832 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS
The invention relates to the treatment of diseases or disorders of the nervous system. In particular, the invention relates to the treatment of diseases or...
2012/0093831 METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS
This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for...
2012/0093830 SINGLE DOMAIN ANTIBODIES THAT BIND IL-13
Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In...
2012/0093829 NEW METHODS FOR TREATMENT OF INFLAMMATORY DISEASES
It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and...
2012/0093828 VACCINE COMPOSITIONS AND METHODS FOR TREATMENT OF MUCORMYCOSIS AND OTHER FUNGAL DISEASES
The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The...
2012/0093827 TREATMENT OF AUTOIMMUNE DISORDERS WITH A NEUROTOXIN
Methods of treating one or more autoimmune disorders include a step of administering a Clostridial neurotoxin, such as a botulinum toxin, to a patient that has...
2012/0093826 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in...
2012/0093825 METHOD FOR PRODUCING ANTIBODY USING "NAKED" EXPRESSION VECTOR EXPRESSING TYPE II TRANSMEMBRANE FUSION PROTEIN
Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector...
2012/0093824 METHODS FOR TREATING PRURITUS BY ADMINISTERING AN ANTIBODY THAT SPECIFICALLY BINDS HUMAN PAR2
The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can...
2012/0093823 HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H5N1 AND USES THEREOF
Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus...
2012/0093822 DOPAMINE D2 RECEPTOR-DISC1 INTERACTION, COMPOSITIONS AND METHODS FOR MODULATING SAME
The present invention provides compounds, compositions and methods for inhibiting D2R-DISC1 interaction. Specifically, the present invention provides a...
2012/0093821 PAPILLOMAVIRUS-LIKE PARTICLES (VLP) AS BROAD SPECTRUM HUMAN PAPILLOMAVIRUS (HPV) VACCINES
This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human...
2012/0093820 Prostatitis-Associated Antigens and Methods of Use Thereof
The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods,...
2012/0093819 ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN
Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are...
2012/0093818 ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and...
2012/0093817 USE OF THE GENES IN THE HOG, Ras AND cAMP PATHWAY FOR TREATMENT OF FUNGAL INFECTION
Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of Cryptococcus...
2012/0093816 Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically...
2012/0093815 FGF21 MUTANTS AND USES THEREOF
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant...
2012/0093814 Fusion Proteins Comprising Canine FC Portions
The present invention relates to therapeutic peptides and proteins fused to a canine antibody Fc domain. Methods and compositions of using the same are described.
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 | Next →